Clinical Trials Sponsored by UCB Pharma GmbH

Total 945 results

UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects

Healthy Male Volunteers

Germany
UCB BIOSCIENCES, Inc.

Completed

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

Partial Epilepsies | Partial Onset Seizures

United States
UCB BIOSCIENCES, Inc.

Completed

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Epilepsy

United States
UCB BIOSCIENCES, Inc.

Completed

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Biopharma S.P.R.L.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects

Healthy Japanese and Caucasian Subjects

United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects

Healthy Male Volunteers

China
UCB Biopharma S.P.R.L.

Completed

A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects

Healthy Volunteers

United Kingdom
UCB BIOSCIENCES GmbH
Schwarz BioSciences GmbH; Alfred-Nobel-Str. 10; 40789 Monheim am Rhein

Completed

Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects

Healthy

Germany
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Lymphoma

United States, Belgium, Japan, Korea, Republic of, Germany, Hong Kong, Hungary, Netherlands, Singapore
UCB Pharma
Biogen

Completed

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

Immune System Diseases | Autoimmune Diseases | Lupus Erythematosus, Systemic | Skin and Connective Tissue Diseases | Connective Tissue Disease

Bulgaria, Belgium, Germany, Poland, Romania, Russian Federation, Spain
UCB Pharma
Biogen

Completed

CDP323 Biomarker Study

Relapsing Multiple Sclerosis

United Kingdom
Pfizer
UCB Pharma

Completed

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

Korea, Republic of, Canada, Belgium, Singapore, United States, Hong Kong, Japan, United Kingdom, France
Pfizer
UCB Pharma

Terminated

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Lymphoma, Non-Hodgkin

Canada, United States, Spain, France, Singapore, Taiwan, Japan, Ireland, Belgium, United Kingdom, Germany, Slovakia, Thailand, Croatia, Czechia, Russian Federation, India, Sweden, Poland, Bulgaria, Hungary, Lithuania, Mexico, Puerto Rico and more
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

B-Cell Lymphoma

United States, Belgium, Korea, Republic of, Switzerland, France, Poland, Spain, Hong Kong, Australia, Germany, Italy, Netherlands, United Kingdom
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, France, United Kingdom, Singapore, Korea, Republic of, Germany
UCB Pharma
Parexel

Completed

Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject

Psoriasis

United Kingdom
UCB Pharma
Parexel

Completed

Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients

Healthy Subjects | Renal Impairments

Japan
UCB Pharma
Biogen

Terminated

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Multiple Sclerosis

United States, France, Germany, Spain, Canada, Netherlands, Belgium, Hungary, Sweden, United Kingdom, Finland
UCB BIOSCIENCES, Inc.
UCB Biopharma SRL

Completed

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Monten... and more
Amgen
UCB Pharma

Completed

Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing (STARTT)

Fracture Healing

Canada, Italy, United States, Russian Federation, France, Germany, Hong Kong, Hungary, Australia, Bulgaria, Poland, Romania, Greece, Denmark, Estonia, India, New Zealand, United Kingdom, Latvia, Slovakia, Lithuania, Mexico, Norway
Pfizer
UCB Pharma

Completed

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States, Canada, France, Spain, China, United Kingdom, Australia, Taiwan, Singapore, Korea, Republic of, Japan, Germany, Czechia, Poland, Italy, Netherlands, Argentina, Finland, Hungary, Sweden
Pfizer
UCB Pharma

Terminated

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Follicular

Belgium, United States, Canada, Hong Kong, Korea, Republic of, Portugal, Spain, Poland, India, Argentina, Italy, Mexico, Russian Federation, South Africa
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia

United States
UCB Biopharma SRL
Parexel

Completed

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Thrombocytopenia

Australia, Bulgaria, Czechia, Georgia, Germany, Italy, Moldova, Republic of, Poland, Romania, Spain, United Kingdom
UCB Japan Co. Ltd.

Completed

A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age (PEACH)

Partial Seizures

Japan
UCB Biopharma S.P.R.L.
Parexel

Completed

A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

Epilepsy

Bulgaria, Finland, France, Germany, Japan, Korea, Republic of, Latvia, Mexico, Philippines, Poland, Romania, Russian Federation, Sweden, Switzerland, Ukraine
UCB Biopharma S.P.R.L.
Parexel

Completed

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 1)

Chronic Plaque Psoriasis

United States, Canada, Czechia, Hungary, Japan, Poland
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

Japan
UCB Japan Co. Ltd.

Completed

Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method

Epilepsy, Partial
UCB Biopharma S.P.R.L.
Parexel

Completed

A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life (CIMAX)

Axial Spondyloarthritis

Belgium, Germany, Greece, Italy, Spain, United Kingdom
UCB Japan Co. Ltd.

Completed

A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)

Epilepsy | Generalized Tonic-Clonic Seizures

China, Japan
UCB Korea Co., Ltd.

Completed

Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures

Epilepsy

Korea, Republic of
UCB Japan Co. Ltd.

Completed

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

Epilepsy | Partial Onset Seizures

Japan
UCB Japan Co. Ltd.

Completed

A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures

Epilepsy | Generalized Tonic-clonic Seizures

Japan
UCB Japan Co. Ltd.

Completed

Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease

Crohn's Disease

Japan
UCB Pharma
UCB Japan Co. Ltd.

Completed

Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method

Epilepsy
UCB Japan Co. Ltd.

Completed

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

Epilepsy | Partial Onset Seizures

Japan
UCB BIOSCIENCES, Inc.
Parexel

Completed

Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

Healthy

United States
UCB Japan Co. Ltd.

Completed

An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures

Epilepsy | Partial Seizures

Japan
UCB Japan Co. Ltd.

Completed

Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males

Healthy Volunteers

Japan
UCB Pharma SA
ReSearch Pharmaceutical Services, Inc.

Completed

Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol (SONAR-12)

Rheumatoid Arthritis

Spain
UCB Biopharma SRL
Parexel

Completed

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Australia, Canada, Moldova, Republic of
UCB Japan Co. Ltd.

Completed

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

Epilepsies | Partial

Japan
UCB Korea Co., Ltd.

Completed

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Idiopathic Parkinson's Disease

Korea, Republic of
Korea UCB Co., Ltd.

Completed

Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy (OPTIMAL)

Epilepsy

Korea, Republic of
UCB Japan Co. Ltd.

Completed

A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures

Epilepsies, Partial

Japan
UCB Japan Co. Ltd.

Completed

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
UCB Pharma
UCB Trading (Shanghai) Co. Ltd.

Completed

Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients

Idiopathic Parkinson's Disease

China
UCB BIOSCIENCES, Inc.
PPD; Parexel

Completed

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (CRADLE)

Rheumatoid Arthritis | Crohn's Disease | Psoriatic Arthritis | Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Non-radiographic Evidence-AxSpA

United States, Netherlands, Switzerland
UCB Celltech
PRA Health Sciences

Completed

Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Czechia, Hungary, Moldova, Republic of, Poland, Russian Federation, Slovakia, United Kingdom

Clinical Trials Sponsored by UCB Pharma GmbH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations